Nikroxx file pdf

1
A
DISSERTATION REPORT
ON
ANALYSIS ON M.I.S. REPORTS OF 10
PHARMACEUTICAL COMPANIES OF PAONTA SAHIB
Submitted to
KURUKSHETRA UNIVERSITY, KURUKSHETRA
In partial fulfillment of the requirement for the award of degree
Of
MASTER OF BUSINESS ADMINISTRATION
SESSION (2014-2016)
UNDER SUPERVISION OF- SUBMITTED BY-
Ms. Meenu Bhutani Nikhil Jhamb
Roll No.-14039
GURU NANAK INSTITUTE OF MANAGEMENT
MULLANA, AMBALA (HARYANA)
(Approved by AICTE, Affiliated to Kurukshetra University, Kurukshetra)

2
DECLARATION
I, NIKHIL JHAMB hereby declare that this research entitled ― Analysis of M.I.S.
Report of various pharmaceutical companies (Mediforce Heathcare Pvt. Ltd.,
Sirmour Remedies Pvt. Ltd., Copmed Pharmaceuticals Pvt. Ltd. UNIT-I,II,III,
Pharma Force Labs UNIT-I,II,III, Relax Pharmaceuticals UNIT-I,II.)‖ submitted
by me for the award of M.B.A. (Final) of Kurukshetra University, Kurukshetra, is the
original work conducted by me and the data provided in the study authentic to the best
of my knowledge.
This research is not submitted to any other Institute or University for the award or
degree of M.B.A.
NIKHIL JHAMB
M.B.A.(Final)

3
ACKNOWLEDGEMENT
There is always a sense of gratitude which one can express for others for their help
and supervision in achieving the goals. I too express my deep gratitude to each and
every one who has been helpful to me in completing the Research report successfully.
I also want to convey my sincere sense of gratitude to Mr. Virender Mehta (
H.O.D., M.B.A. Deptt.) for their inspiration & helpful attitude. I would like to grab
the opportunity to thank Ms. Meenu Bhutani ( Faculty, M.B.A. Deptt.) for her
helping hand in the completion of the Research report.
I feel self-short of words to thanks my parents and friends who had directly or
indirectly help me in the completion of the Research report. I would also like to thank
Almighty God for blessing showered on me during the completion of Research
report.
NIKHIL JHAMB

4
EXECUTIVE SUMMARY
As we are experiencing that Pharmaceuticals is the biggest necessity in any country.
Due to lacking in this sector India is far behind the developed countries. In this
research I have included India’s 10 Pharmaceutical Companies they are induldge in
this business.
M.I.S. Reports show the real picture of the companies’ functions, operations,
liabilities and assets. Study of their M.I.S. Reports show growth of the companies,
that they are earning good profit and as well as distributing good amount of dividends.
In my study, I tried to cover all the financial aspects and throw a light on the
profitability of the companies which shows that there is high risk in the industry in
India.
I have done research on the M.I.S. report of 10 different pharmaceutical companies
and did the interpretation on the basis of sales , profit and overheads of the companies
by comparing it with their last year’s sales, profit and overheads.

5
Declaration
Acknowledgement
Executive Summary
CONTENTS
TITLE PAGE NO.
Chapter 1.Introduction
1.1 Pharmaceutical Industry - 1-16
1.2 Company Profile - 17-32
Chapter 2.
Management Information
System - 33-43
Chapter 3. Research methodology
3.1 Objective of the study - 44
3.2 Research design - 44
3.3 Data Collection - 45
Chapter 4. Data analysis and interpretation - 46-55
Chapter 5. Findings - 56
Chapter 6. Recommendations and Conclusion - 57-58
Bibliography - 59

6
INTRODUCTION
Pharmaceutical industry, the discovery, development, and manufacture of drugs and
medications (pharmaceuticals) by public and private organizations. The modern era of
the pharmaceutical industry—of isolation and purification of compounds, chemical
synthesis, and computer-aided drug design—is considered to have begun in the 19th
century, thousands of years after intuition and trial and error led humans to believe
that plants, animals, and minerals contained medicinal properties. The unification of
research in the 20th century in fields such as chemistry and physiology increased the
understanding of basic drug-discovery processes. Identifying new drug targets,
attaining regulatory approval from government agencies, and refining techniques in
drug discovery and development are among the challenges that face the
pharmaceutical industry today. The continual evolution and advancement of the
pharmaceutical industry is fundamental in the control and elimination
of disease around the world.
The Indian pharmaceutical industry currently tops the chart amongst India's science-
based industries with wide ranging capabilities in the complex field of drug
manufacture and technology. A highly organized sector, the Indian pharmaceutical
industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent
annually. It ranks very high amongst all the third world countries, in terms of
technology, quality and the vast range of medicines that are manufactured.

7
The Indian pharmaceutical sector is highly fragmented with more than 20,000
registered units. It has expanded drastically in the last two decades. The
Pharmaceutical and Chemical industry in India is an extremely fragmented market
with severe price competition and government price control. The Pharmaceutical
industry in India meets around 70% of the country's demand for bulk drugs, drug
intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and
injectibles. There are approximately 250 large units and about 8000 Small Scale
Units, which form the core of the pharmaceutical industry in India (including 5
Central Public Sector Units).
The Government has also played a vital role in the development of the India Software
Industry. In 1986, the Indian government announced a new software policy which
was designed to serve as a catalyst for the software industry. This was followed in
1988 with the World Market Policy and the establishment of the Software
Technology Parks of India (STP) scheme. In addition, to attract foreign direct
investment, the Indian Government permitted foreign equity of up to 100 percent and
duty free import on all inputs and products.
Current Scenario
The industry has enormous growth potential. Factors listed below determine the rising
demand for pharmaceuticals.
 The growing population of over of a billion
 Increasing income
 Demand for quality healthcare service
 Changing lifestyle has led to change in disease patterns, and increased demand
for new medicines to combat lifestyle related diseases.More than 85 per cent
of the formulations produced in the country are sold in the domestic market.
India is largely self-sufficient in case of formulations. Some life saving, new
generation under-patent formulations continue to be imported, especially by
MNCs, which then market them in India. Overall, the size of the domestic
formulations market is around Rs160 billion and it is growing at 10 per cent
per annum

8
Diagnostic Outsourcing/ Clinical Trails
The Indian diagnostic services are projected to grow at a CAGR of more than 20 per
cent during 2010-2012.
Some of the major Indian pharmaceutical firms, including Sun Pharma, Cadilla
Healthcare and Piramal Life Sciences, had applied for conducting clinical trials on at
least 12 new drugs in 2010, indicating a growing interest in new drug discovery
research.
Generics
India tops the world in exporting generic medicines worth US$ 11 billion and
currently, the Indian pharmaceutical industry is one of the worlds largest and most
developed.
Moreover, the Indian generic drug market to grow at a CAGR of around 17 per cent
between 2010-11 and 2012-13. Union Minister of Commerce and Industry and
Minister for Trade and Industry, Singapore, have signed a 'Special Scheme for
Registration of Generic Medicinal Products from India' in May 2010, which seeks to
fast-track the registration process for Indian generic medicines in Singapore.
Advantage India
The Indian Pharmaceutical Industry, particularly, has been the front runner in a wide
range of specialties involving complex drugs' manufacture, development and
technology. With the advantage of being a highly organized sector, the
pharmaceutical companies in India are growing at the rate of $ 4.5 billion, registering
further growth of 8 - 9 % annually.
More than 20,000 registered units are fragmented across the country and reports say
that 250 leading Indian pharmaceutical companies control 70% of the market share
with stark price competition and government price regulations.
Competent workforce: India has a pool of personnel with high managerial and
technical competence as also skilled workforce. It has an educated work force and
English is commonly used. Professional services are easily available.

9
Cost-effective chemical synthesis: Its track record of development, particularly in the
area of improved cost-beneficial chemical synthesis for various drug molecules is
excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk
drugs.
Legal & Financial Framework: India has a 53 year old democracy and hence has a
solid legal framework and strong financial markets. There is already an established
international industry and business community.
Information & Technology: It has a good network of world-class educational
institutions and established strengths in Information Technology.
Globalization: The country is committed to a free market economy and globalization.
Above all, it has a 70 million middle class market, which is continuously growing.
Consolidation: For the first time in many years, the international pharmaceutical
industry is finding great opportunities in India. The process of consolidation, which
has become a generalized phenomenon in the world pharmaceutical industry, has
started taking place in India.

11
KEY POINTS REGARDING PHARMACEUTICAL INDUSTRY
Supply
Higher for traditional therapeutic segments, this is typical of a developing market. Relatively
lower for lifestyle segment.
Demand
Very high for certain therapeutic segments. Will change as life expectancy, literacy increases.
Barriers to entry
Licensing, distribution network, patents, plant approval by regulatory authority.
Bargaining power of suppliers
Distributors are increasingly pushing generic products in a bid to earn higher margins.
Bargaining power of buyers
High, a fragmented industry has ensured that there is widespread competition in almost all
product segments. Currently, the domestic market is also protected by the DPCO.
Competition
High. Very fragmented industry with the top 300 (of 24,000 manufacturing units) players
accounting for large chunk of sales. Top 20 companies account for 60% of the IPM sales.

12
INDIAN PHARMACEUTICAL INDUSTRY
Introduction
The Indian pharmaceuticals market is third largest in terms of volume and thirteen
largest in terms of value, as per a pharmaceuticals sector analysis report by equity
master. The market is dominated majorly by branded generics which constitute nearly
70 to 80 per cent of the market. Considered to be a highly fragmented industry,
consolidation has increasingly become an important feature of the Indian
pharmaceutical market.
India has achieved an eminent global position in pharmacy sector. The country also
has a huge pool of scientists and engineers who have the potential to take the industry
to a very high level.
Market Size
The Indian pharmaceutical industry is estimated to grow at 20 per cent compound
annual growth rate (CAGR) over the next five years, as per India Ratings, a Fitch
Group company. Indian pharmaceutical manufacturing facilities registered with US
Food and Drug Administration (FDA) as on March 2014 was the highest at 523 for
any country outside the US. We expect the domestic pharmacy market to grow at 10-
12 per cent in FY15 as compared to 9 per cent in FY14, as per a recent report from
Centrum Broking. The domestic pharma growth rate was 11.9 per cent in October
2014, highlighted the report.Gujarat clocked the highest growth rate in
pharmaceuticals market at 22.4 per cent during November 2014, surpassing the

13
industry growth rate, which grew by 10.9 per cent, as per data from the market
research firm AIOCD Pharma softtech AWACS.
Also, growing at an average rate of about 20 per cent, India's biotechnology industry
comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and
bioinformatics may reach the US$ 7 billion mark by the end of FY15, according to an
industry body. Bio-pharma is the largest sector contributing about 62 per cent of the
total revenue, with revenue generation to the tune of over Rs 12,600 crore (US$ 2.03
billion). The bio-pharma sector comprises vaccines, therapeutics and diagnostics.
Investments
 The Union Cabinet has given its approval to amend the existing FDI policy in
the pharmaceutical sector in order to cover medical devices. The Cabinet has
allowed FDI up to 100 per cent under the automatic route for manufacturing of
medical devices subject to specified conditions.
 The drugs and pharmaceuticals sector attracted cumulative foreign direct
investment (FDI) inflows worth US$ 12,813.02 million between April 2000
and December 2014, according to data released by the Department of
Industrial Policy and Promotion (DIPP).
 Stelis Biopharma has announced the ground-breaking for construction of its
customized, multi-product, biopharmaceutical manufacturing facility at Bio-
Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's park and ecosystem
for industrial and healthcare biotechnology at a total project investment
amount of US$ 60 million.
 Pharma major Strides Arco lab has entered into a licensing agreement with
US-based Gilead Sciences Inc to manufacture and distribute the latter's low-
cost Tenofovir Alafenamide (TAF) product used for HIV treatment in
developing countries. The license to manufacture Gilead's low-cost drug
extends to 112 countries.
 Apollo Hospitals Enterprise (AHEL) plans to add another 2,000 beds over the
next two financial years, at a cost of around Rs 1,500 crore (US$ 242.57
million), as per Mr. Prathap C Reddy, Founder and Executive Chairman,
Apollo Hospitals.

14
 CDC, the UK’s development finance institution, has invested US$ 48 million
in Narayana Hridayalaya hospitals, a multi-speciality healthcare provider.
With this investment, Narayana Health will expand affordable treatment in
eastern, central and western India.
 Cadila Healthcare Ltd has announced the launch of a biosimilar for
Adalimumab - the world’s largest selling drug for rheumatoid arthritis and
other auto immune disorders. The drug will be marketed under the brand name
Exemptia at one-fifth of the price for the branded version-Humira.
Cadila’sbiosimilar is the first to be launched by any company in the world and
is a finger print match with the original in terms of safety, purity and potency
of the product, as per the company.
Government Initiatives
The Addendum 2015 of the Indian Pharmacopoeia (IP) 2014 is published by the
Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health &
Family Welfare, Government of India. The addendum would play a significant role in
improving the quality of medicines which in turn promote public health and
accelerate the growth and development of pharma sector.
The Government of India has unveiled 'Pharma Vision 2020' aimed at making India a
global leader in end-to-end drug manufacture. It has reduced approval time for new
facilities to boost investments. Further, the government has also put in place
mechanisms such as the Drug Price Control Order and the National Pharmaceutical
Pricing Authority to address the issue of affordability and availability of medicines.
Romania is keen to tie up with the Indian pharmaceutical companies for research and
develop new drugs. "Romania will collaborate with India for license acquisition to
sale India's drugs in Europe," said Mr. Mario Crute, Counselor in Ministry of health
in Romania at GCCI. The country will tie up with the Indian pharmaceutical
companies for research and develop new drugs.
Some of the major initiatives taken by the government to promote the pharmaceutical
sector in India are as follows:

15
Indian and global companies have expressed 175 investment intentions worth Rs
1,000 crore (US$ 161.78 million) in the pharmaceutical sector of Gujarat. The
memorandums of understanding (MOUs) would be signed during the Vibrant Gujarat
Summit.
Telangana has proposed to set up India's largest integrated pharmaceutical city spread
over 11,000 acres near Hyderabad, complete with effluent treatment plants and a
township for employees, in a bid to attract investment of Rs 30,000 crore (US$ 4.85
billion) in phases. Hyderabad, which is known as the bulk drug capital of India,
accounts for nearly a fifth of India's exports of drugs, which stood at Rs 90,000 crore
(US$ 14.56 billion) in 2013-14.
Road Ahead
The Indian pharma market size is expected to grow to US$ 85 billion by 2020. The
growth in Indian domestic market will be on back of increasing consumer spending,
rapid urbanization, raising healthcare insurance and so on.
Going forward, better growth in domestic sales will depend on the ability of
companies to align their product portfolio towards chronic therapies for diseases such
as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers are on the
rise.
Emerging Trend
The Indian pharmaceutical industry is now discovering new opportunities of growth
in clinical research, contract research, manufacturing and innovation opportunities.
This path can lead the Indian pharmaceutical industry to huge success endeavors.
Research & Development
Research & Development is the key to the future of pharmaceutical industry. The
pharmaceutical advances for considerable improvement in life expectancy and health
all over the world are the result of a steadily increasing investment in research. There
is considerable scope for collaborative R & D in India. India can offer several
strengths to the international R & D community. These strengths relate to availability
of excellent scientific talents who can develop combinatorial chemistry, new synthetic
molecules and plant derived candidate drugs

16
The R & D expenditure by the Indian pharmaceutical industry is around 1.9 per cent
of the industry‟s turnover, which is a little low as compared to foreign research based
pharmaceutical companies. However, now that India is entering into the Patent
protection area, many companies are spending relatively more on R & D. When it
comes to clinical evaluation at the time of multi-center trials, India is providing a
strong base considering the real availability of clinical materials in diverse therapeutic
areas. According to a survey by the Pharmaceutical Outsourcing Management
Association and Bio/Pharmaceutical Outsourcing Report, pharmaceutical companies
are utilizing substantially the services of Contract Research Organizations (CROs).
Indian Pharmaceutical Industry, with its rich scientific talents, provides cost-effective
clinical trial research. It has an excellent record of development of improved, cost-
beneficial chemical syntheses for various drug molecules. Some MNCs are already
sourcing these services from their Indian affiliates.
Product development
For years, firms have made their ways into the global market by researching generic
competitors to patented drugs and following up with litigation to challenge the patent.
This approach remains untouched by the new patent regime and looks to increase in
the future.However, those that can afford it have set their sights on an even higher
goal: new molecule discovery. Although the initial investment is huge, companies are
lured by the promise of hefty profit margins and the recognition as a legitimate
competitor in the global industry.
Small and medium enterprises
The excise structure changed so that companies now have to pay a 16 per cent tax on
the maximum retail price of their products, as opposed to on the ex-factory price.
Consequently, larger companies are cutting back on outsourcing and what business is
left is shifting to companies with facilities in the four tax-free states - Himachal
Pradesh, Jammu & Kashmir, Uttaranchal and Jharkhand. SMEs have been finding it
difficult to find the funds to upgrade their manufacturing plants, resulting in the
closure of many facilities. In terms of the global market, India currently holds a
modest 1-2 per cent share, but it has been growing at approximately 10 per cent per
year.

17
Revenue of Indian pharmaceutical industry
The Indian pharmaceuticals market is expected to expand at a CAGR of 23.9 per cent
to reach US$ 55 billion by 2020.

18
Swot Analysis of Indian Pharmaceutical Industry
Strength
Low cost of raw material (API) for production. Large pool of installed capacities with
skilled manpower. Efficient technologies for large number of Generics. Large pool of
increasing liberalization of government policies.
Weakness
Very low R&D facilities. Fragmentation of installed capacities. Low technology level
of Capital Goods of this section. Non-availability of major intermediaries for bulk
drugs. Lack of experience to exploit efficiently the new patent regime. Low level of
strategic planning for future and also for technology forecasting.
Opportunities
Growth in the emerging branded generic market Growing incomes. Growing attention
forhealth.New therapy approaches. New delivery systems. Spreading attitude for soft
medication (OTC drugs).Spreading use of Generic Drugs. Easier international trading.
Threats
Stiff Competition both from local as well as global players particularly from generic
products. Increased due diligence and action on default compliance with standards
High Cost of discovering new products and fewer discoveries Stricter registration
procedures.

19
Different departments working in the head office are
1.Marketing and Sale
2. Human Resources
3. Financial Accounting & Revenue Assurance
4. Administration
5. Procurement & Logistics
6. Quality Control
7. Quality Assurance
8. International Business (Exports)
9. Information Technology

20
CHALLENGES & FUTURE GROWTH
Challenges
Over the past decade, pharmaceutical companies have entered a difficult period where
shareholders, the market and regulators have created significant pressures for change
within the industry. The core issues for most of drug companies are declining
productivity of in-house R & D, patent expiration of number of block buster drugs,
increasing legal and regulatory concern, and pricing issue. As a result larger
pharmaceutical companies are shifting to new business model with greater
outsourcing of discovery services, clinical research and manufacturing.
Current global financial conditions and the threat of a broad recession accelerated the
timetable for implementing transformational changes in global organizations, as the
industry confronts lower corporate stock prices and an increasingly cost-averse
customer. Leaders of the largest global pharmaceutical companies recognize the need
for transformational change in their organizations, but will need to move swiftly to
ensure sustained growth.
Transformations in the business model of larger pharmaceutical industry spell more
opportunities for Indian pharmaceutical companies. Pharmaceutical production costs
are almost 50 percent lower in India than in western nations, while overall R&D costs
are about one-eighth and clinical trial expenses around one-tenth of western levels.
The Indian stock market may be dreading a possible recession but Indian pharma
companies seem unfazed by slowdown fears. Riding on better sales in the domestic
and export markets, Indian pharmaceutical industry is expected to continue with its
good perform ance. Today Indian pharmaceutical Industry can look forward to the
years to come, with great expectations. There are opportunities in expanding the
range of generic products as more molecule come off patent, outsourcing, and above
all, in focusing into drug discovery as more profits come from traditional plays.
At the same time, the Indian Pharma Industry would have to contend with several
challenges particularly the :-
• Effects of new product patent

21
• Drug price control
• Regulatory reforms
• Infrastructure development
• Quality management and .
Growth
The Indian pharmaceutical market reached US$ 10.04 billion in size, with a value-
wise growth rate of 20.4 per cent over the previous year's corresponding period on a
Moving Annual Total (MAT) basis for the 12 months ended July 2010.
Cipla maintained its leadership position in the domestic market with 5.27 per cent
share followed by Ranbaxy. The highest growth in the domestic market was for
Mankind Pharma which grew 37.2 per cent. Leading companies in the domestic
market such as Sun Pharma(25.7per cent), Abbott (25 per cent), Zydus Cadila (24.1
per cent), Alkem Laboratories (23.3 per cent), Pfizer (23.6 per cent), GSK India (19
per cent), Piramal Healthcare (18.6 per cent) and Lupin (18.8 per cent) had impressive
growth during July 2010, shows the data.

22
VARIOUS COMPANIES ON WHICH M.I.S. ANALYSIS HAS
BEEN DONE
 MEDIFORCE HEATHCARE PVT. LTD.
 SIRMOUR REMEDIES PVT. LTD.
 COPMED PHARMACEUTICALS PVT. LTD. UNIT-I
 COPMED PHARMACEUTICALS PVT. LTD. UNIT-II
 COPMED PHARMACEUTICALS PVT. LTD. UNIT-III
 PHARMA FORCE LABS UNIT-I
 PHARMA FORCE LABS UNIT-II
 PHARMA FORCE LABS UNIT-III
 RELAX PHARMACEUTICALS UNIT-I
 RELAX PHARMACEUTICALS UNIT-II

23
MEDIFORCE HEALTHCARE PVT.LTD.
Mediforce Healthcare Private Limited is a Private Company incorporated on 14
February 2001. It is classified as Indian Non-Government Company and is registered
at Registrar of Companies, Kanpur. Its authorized share capital is Rs. 15,000,000 and
its paid up capital is Rs. 11,400,000.Mediforce Healthcare Private Limited's Annual
General Meeting (AGM) was last held on 29 September 2014 and as per records from
Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March
2014.
MediforceHeathcare Pvt. Ltd. Is a third party manufacturing unit of UnikindPharma
working for Mankind Pharma.
Directors of Mediforce Healthcare Private Limited are Veer Pal Singh and
BrijeshwarDuttTyagi.
Mediforce Healthcare Private Limited's Corporate Identification Number is (CIN)
U501397UP2001PTC025873 and its registration number is 25873.Its Email address is
caguptashiv@gmail.com and its registered address is A-25, DEFENCE COLONY,
MEERUT - 250001, Uttar Pradesh INDIA.
Current status of Mediforce Healthcare Private Limited is - Active.

24
PRODUCTS OF MEDIFORCE HEATHCARE PVT.LTD.
Product Name - Geniric Code
AMLOKIND-5 - Amlodipine Besilate tablets IP
AMLOKIND-10 - Amlodipine Besilate tablets IP
AMLOKIND-AT - Amlodipine tablets
RANIDOM - Omeprazole Magnesium tablets
RANISPAS - Omeprazole Magnesium tablets
AMLOKIND-L - Losartan potassium tablets IP
RABEKIND-20 - Rabeprazole Sodium tablets IP

25
SIRMOUR REMEDIES PVT.LTD.
Sirmour Remedies Private Limited is a Private Company incorporated on 12 October
1989. It is classified as Indian Non-Government Company and is registered at
Registrar of Companies, Himachal Pradesh. Its authorized share capital is Rs.
20,000,000 and its paid up capital is Rs. 10,000,000.Sirmour Remedies Private
Limited's Annual General Meeting (AGM) was last held on 30 September 2014 and
as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last
filed on 31 March 2014.Sirmour Remedies Pvt. Ltd. is a third party manufacturing
unit of UnikindPharma working for Mankind Pharma.Directors of Sirmour Remedies
Private Limited are Veer Pal Singh, ShyamLal and BrijeshwarDuttTyagi.Sirmour
Remedies Private Limited's Corporate Identification Number is (CIN)
U15311HP1989PTC009770 and its registration number is 9770.
Its Email address is caguptashiv@gmail.com and its registered address is VPO Majra
Sirmour ,Paonta Sahib - 173021, Himachal Pradesh INDIA.
Current status of Sirmour Remedies Private Limited is - Active.

26
PRODUCTS OF SIRMOUR REMEDIES PVT LTD.
Product Name - Generic Code
BRUTACEF DRY SYRUP - Cefixime Oral suspension
MAHACEF DRY SYRUP - CefpodoximeProxetil oral suspension
GUDCEF DROPS - CefpodoximeProxetil Oral suspension
GUDCEF DS DROPS - CefpodoximeProxetil oral suspension
GUDCEF DRY SYRUP - Cefixime Oral suspension

27
COPMED PHARMACEUTICALS PVT.LTD.
Copmed Pharmaceuticals Private Limited is a Private Company incorporated on 13
September 1988. It is classified as Indian Non-Government Company and is
registered at Registrar of Companies, Delhi. Its authorized share capital is Rs.
20,000,000 and its paid up capital is Rs. 9,600,000.Copmed Pharmaceuticals Private
Limited's Annual General Meeting (AGM) was last held on 29 September 2014 and
as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last
filed on 31 March 2014.Copmed Pharmaceuticals Pvt. Ltd. Is a third party
manufacturing unit of UnikindPharma working for Mankind Pharma. Directors of
Copmed Pharmaceuticals Private Limited are Veer Pal Singh and
BrijeshwarDuttTyagi. Copmed Pharmaceuticals Private Limited's Corporate
Identification Number is (CIN) U74899DL1988PTC033151 and its registration
number is 33151.Its Email address is caguptashiv@gmail.com and its registered
address is 7,VASANT MARG, IIND FLOOR VASANT VIHAR, NEW DELHI -
110057, Delhi INDIA.
Current status of Copmed Pharmaceuticals Private Limited is - Active.
There are three units of CopmedPharmaceuticals in Paonta Sahib, DisttSirmour,
(H.P.)

28
COPMED PHARMACEUTICALS PVT. LTD. UNIT-I
Address- Plot no-50 GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP
PRODUCTS OF COPMED PHARMACEUTICALS PVT. LTD. UNIT-I
THYROCHEK-100 TABLETS - L-Thyroxin Sodium Tablets
ELECTROKIND (4.3G) - Oral Rehydration salt
ELECTROKIND-Z(4.3G) - Oral Rehydration salt
ELECTROKIND (21.5G) - Oral Rehydration salt
ARGIPRG (6.5G) - Oral Rehydration salt
ARGIPRG (5.0G) - Oral Rehydration salt
ELECTROKIND-Z (21.5G) - Oral Rehydration salt

29
COPMED PHARMACEUTICALS PVT. LTD. UNIT-II
Address- Plot no- 45, GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP
PRODUCTS OF COPMED PHARMACEUTICALS PVT. LTD. UNIT-II
SUCRADAY SUSPENSSION - Sucralaphate suspension
SUCRADAY -O SUSPENSION - Sucralaphate+Oxetacaine
CIPROGYL SUSPENSION - Ciprofloxacin and Metronidazole
TEDYKOFF COUGH SYRUP - Chlorpheniramine Maleate
CODISTAR-DX - Dextromethorphan Hydrobromide
ZENFLOX-OZ SUSPENSION - Ofloxacin and Ornidazol

30
COPMED PHARMACEUTICALS PVT. LTD. UNIT-III
Address- Plot no- 25 & 26, GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP
PRODUCTS OF COPMED PHARMACEUTICALS PVT. LTD. UNIT-III
MEFKIND FORT - Ofloxacin suspension
MEFKIND-P - Mefenamic acid oral suspension
NOBLOK SYRUP - SodiumCitrate syrup
HICOPE SYRUP - Hydroxyzine Hydrochloride oral
NOBEL PLUS - Paracetamol&Mefenamic Acid
ZENFLOX SUSPENSION - Paracetamol&Mefenamic Acid

31
PHARMA FORCE LABS PVT.LTD.
Pharma Force Labs is a member of Mankind group, a leading brand in pharmacy.
Pharma Force Labs is a Private Company incorporated on 13 September 1988. It is
classified as Indian Non-Government Company and is registered at Registrar of
Companies, Delhi. Its authorized share capital is Rs. 20,000,000 and its paid up
capital is Rs. 9,600,000. Pharmaforcelabs Annual General Meeting (AGM) was last
held on 29 September 2014 and as per records from Ministry of Corporate Affairs
(MCA), its balance sheet was last filed on 31 March 2014.Pharmaforcelabs is a third
party manufacturing unit of Unikind Pharma working for Mankind Pharma.Directors
of Pharmaforcelabs Private Limited are Veer Pal Singh and Brijeshwar Dutt Tyagi.
Pharma Force Labs Corporate Identification Number is (CIN)
U74899DL1988PTC033151 and its registration number is 33151.Its Email address is
caguptashiv@gmail.com and its registered address is 7,VASANT MARG, IIND
FLOOR VASANTVIHAR,NEWDELHI-110057,Delhi,INDIA.
Current status of Pharmaforcelabs is - Active.
There are three units of Pharmaforcelabs in Paonta Sahib, Distt Sirmour, (H.P.)

32
PHARMA FORCE LABS PVT. LTD. UNIT-I
ADDRESS-- Plot no- 76, GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP
PRODUCTS OF PHARMA FORCE LABS UNIT-I
CODISTAR COUGH SYRUP - Codeine Phosphate Syrup
T-98 SUSPENSION - Acetaminophen oral suspension
T-98PLUS SUSPENSION - Promethazine Hydrochloride
T-98 DS SUSPENSION - Acetaminophen oral suspension
TEDYKOFF-LX COUGH SYRUP - Pholcodine syrup

33
PHARMA FORCE LABS PVT. LTD. UNIT-II
ADDRESS-- Plot no- 86,87, GONDPUR INDUSTRIALAREA, PAONTA SAHIB,
HP.
PRODUCTS OF PHARMA FORCE LABS UNIT-II
CEFAKIND-125 DT TABLETS - CefpodoximeProxetile Dispersible
Tablets
GUDCEF-200 TABLETS - Cefixime Tablets
GUDCEF-100 DT TABLETS - Cefixime Dispersible Tablets
GUDCEF-50 DT TABLETS - Cefixime Dispersible Tablets
MAHACEF-200 - Cefixime and Ofloxacine tablets
MAHACEF-50 DT - Cefuroxime Axetil Dispersible Tablets
MAHACEF-100 DT - Cefuroxime Axetil Dispersible Tablets

34
PHARMA FORCE LABS PVT. LTD. UNIT-III
ADDRESS-- Plot no- 24,25, GONDPUR INDUSTRIALAREA, PAONTA SAHIB,
HP.
PRODUCTS OF PHARMA FORCE LABS UNIT-III
MAHACEF –PLUS - Cefixime and Ofloxacine tablets
ZENFLOX-PLUS 100 - Cefixime and Ofloxacine tablets
MAHACEF-OZ - Cefixime and Ornidazole Tablets
MAHACEF-400 - Cefixime Tablets
MAHACEF-PLUS 100 - Cefixime and Ofloxacine Dispersible tablets

35
RELAX PHARMACEUTICALS
Relax Pharmaceuticals is an Ethical and Generic Pharmaceutical manufacturer of high
quality products as per GMP Standards.Relax Pharmaceuticals was promoted in 1994
by visionaries Shri K. D. Patel, a Pharmacist and Shri D. R. Patel, an
Industrialist. Shri K. D. Patel is a Bachelor in Pharmacy who has overall experience
of 15 years in production of various pharmaceutical dosage companies. He also had a
rich stint of 5 years as Work Manager in an Export Oriented Firm M/s Hamax
Pharmaceuticals, Baroda. Shri D. R. Patel is a well known industrialist having a sound
financial background. He is engaged in manufacturing of epoxy moulded, current
transformers and Resin Products. He enjoys a credible name due to superior quality of
products which are well accepted in Government Departments and reputed Private
Companies. The company has gradually established a strong foothold on production
of various pharmaceuticals which covers a comprehensive range:Tablets: Antacids,
Analgesics, Antihypertensives Sedatives & hypnotics, Anti diahhoreals. CAPSULES :
Antibiotics, B-Complex &Haematinics. Liquid Orals: C-Complex, Haematinics,
Antacids Cough Syrups, Protein Syrup. Anti bacterials, Anti diahhoreals etc.Current
status of Relax Pharmaceuticals- Active.
Relax Pharmaceuticals is working in Paonta Sahib under 2 units.

36
RELAX PHARMACEUTICALS UNIT-I
ADDRESS- Plot No.46, GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP.
PRODUCTS OF RELAX PHARMA PVT. LTD. UNIT-I
UNWANTED TABLETS - Mifepristone Tablets
GYNASET TABLETS - Norethistrone Tablets
UNWANTED-72TABLETS - Levonorgestrel Tablets
PRESTAKIND TABLETS - Misoprostol Tablets
THYROCHEK-50 TABLETS - Thyroxin Sodium Tablets
UNWANTED-KIT - Mifepristone&Misoprostol Tablets
UNWANTED-21 DAYS - levonorgestrel Tablet

37
RELAX PHARMACEUTICALS UNIT-II
ADDRESS- Plot No.58, GONDPUR INDUSTRIALAREA, PAONTA SAHIB, HP.
PRODUCTS OF RELAX PHARMA PVT. LTD. UNIT-II
BRUTACEF-200 TABLETS - Cefixime Tablets
BRUTACEF-O TABLTES - Cefixime and Ofloxacin Tablets
BRUATCEF-O 100 TABLETS - Ofloxacin Dispersible Tablets
BRUTACEF -AZ 250 - Cefixime and Azithromycin Tablets
BRUTACEF-AZ500 - Cefixime and Azithromycin Tablets
CEFAKIND-500 TABLETS - Cefuroxime Axetil Tablets
CEFAKIND-250 TABLETS - Cefuroxime Axetil tablets

38
Management Information Systems (MIS)
An MIS provides managers with information and support for effective decision
making, and provides feedback on daily operations.
A manufacturing MIS can help managers monitor a manufacturing process to
maximize the value to processes within an organization.
Information is provided to managers through various summary reports that are usually
generated through accumulation of transaction processing data.
Each MIS is an integrated collection of subsystems, which are typically organized
along functional lines within an organization.
Thus, a financial MIS includes subsystems that address financial reporting, profit and
loss analysis, cost analysis, and the use and management of funds.
Sources of Management Information
Management information systems is one of the systems that managers use to obtain
information. Other systems include decision support systems, executive support
systems and expert systems.

39
Data Inputs to an MIS
1. Most of the data source for MIS is the organization’s various transaction
processing systems that capture and store data from ongoing business transactions.
2. Data may also come from various functional areas (accounting, finance, sales,
etc.) of an organization.
3. External sources of data may include customers, suppliers, competitors,
stockholders, and so on.
Outputs of an MIS
1. The output of most management information systems is a collection of reports that
are distributed to managers. These include scheduled reports, key-indicator
reports, demand reports, exception reports, and drill-down reports.
Characteristics of an MIS
A management information system performs the following functions:
1. Provides reports with fixed and standard formats:
2. All reports are produced in an easy-to-read and standard format, so managers in
various functional areas find consistencies in reports.
3. Produces hard-copy and soft-copy reports:
4. Standard reports are typically printed on papers and they are termed as hard copy
5. Soft copy reports are displayed on computer screens.

40
Uses internal data stored in the computer system:
1. MIS reports use primarily internal sources of data that are contained in
computer databases (through TPSs).
2. End users are able to develop their own custom reports:
3. Although most of the standard reports are designed by and analyst, the users
should be able to develop reports on an ad-hoc basis.
Functional Aspects of the MIS
1. A management information system is organized according to the business
functionality of an organization.
2. Thus an MIS contains systems in areas of accounting, human resources,
marketing, manufacturing, research and development, legal services,
operations/support, and finance.
3. Each functional system uses its own set of function-specific subsystems, all of
which interface with both the TPS and the MIS.
4. Each functional system requires different information and support for decision
making; but they share some common information needs.
Financing decisions are one of the most critical areas and the challenging job for the
finance managers, because, It has direct impact on the financial performance and
capital structure of the companies. The finance manager of every company is always
looking to maximize the economic welfare of the owners as represented by the market
value of the firm. For this purpose, he has to take number of decisions like
investment, financing and dividend decisions. The financing decision is mainly
involves two choices. The first is the dividend choice – the distribution of retained
earnings to be ploughed back and to be paid out as dividends.
The second is a choice of capital structure – the proportion of external finance to be
borrowed and the proportion to be raised in the form of new equity. In real sense, the
decisions about both the choice should not impact on the value of the firm. Because
these decisions are related to either the form of distribution, type of security, or make
up of the ownership structure, but not to the investment decision. Generally, the firms

41
have the internal and external sources of fund in its capital structure to finance their
investments. Internal sources include retained earnings and depreciation; whereas the
external sources consist of new borrowings or the issue of shares.
Capital structure decisions have great impact on the firm’s financial
performance.
Exactly how firms choose the amount of debt and equity in their capital structures
remains an enigma. Capital structure is the combination of debt and equity that
finance the organization's strategic plan. The effective management of capital
structure ensures the availability of required fund to finance the future growth and
enhance the financial performance. The debt equity relationship is depends upon the
nature of industries involved like company's line of business and its development. A
company is said to be highly leveraged, if it includes the maximum debt source of
finance in its capital structure, which results, the company find its freedom of action
restricted by its creditors and may have its profitability affected with the payment of
high interest costs. There is a significant difference between the industry and the
individual companies within an industry in terms of capital structure. There are
number of factors influencing the capital structure decision of the company, but the
judgment of the person making the capital structure decision plays a crucial part. Two
similar companies can have different capital structures as per the different judgement
of decision makers with the significance of various factors. Thus, the financing
decisions have no affect on firm value, as it is the residue of the more important
investment decisions. Similarly, this paper is an attempt to determining the impact of
variations in the capital structures of various pharmaceutical companies on their
investment pattern over the period of time and highlighting the importance of debt
capital and equity capital to determining the value of investments of the companies.

42
In the recent time, financial manager always plans an optimum capital structure for
his company to obtain the higher market value per share. An optimal capital structure
is usually defined as one that will maximizing shareholder’s wealth by minimize the
firm's cost of capital. Capital structure decisions have great impact on the firm’s
financial performance. Exactly how firms choose the amount of debt and equity in
their capital structures still an enigma. There are number of factors influencing the
capital structure decision of the company, but the judgment of the person making the
capital structure decision plays a crucial part. Two similar companies can have
different capital structures as per the different judgement of decision makers with the
significance of various factors. Thus, the financing decisions have no affect on firm
value, as it is the residue of the more important investment decisions. Therefore,
firms, managers, and investors, devote more time and resources to making the
financing decisions about dividends and capital structure. Similarly, this study also
conclude that the capital structure decision of the pharmaceutical companies has very
little effect on its investment pattern, which defines that the company is using long
term sources of funds to finance its current assets and its operational activities of its
business with the object to attain the long term solvency and maximising profitability
with least cost of capital.
Since, last two decades of Indian economy, there is a continue research on company
financing activities, particularly aimed at understanding how companies finance their
investments and what source they used to finance. In practice, it is observed that
finance managers use different combinations of debt and equity to meet the various
financial requirements of the company at least cost and risk and for the long term
benefit of the company.

43
Financial MIS
Inputs to the Financial MIS
Strategic plan or corporate policies
Contains major financial objectives and often projects financial needs.
Transaction processing system (TPS)
Important financial information collected from almost every TPS - payroll, inventory
control, order processing, accounts payable, accounts receivable, general ledger.
External sources
Annual reports and financial statements of competitors and general news items.

44
Financial MIS Subsystems and Outputs
1. Profit/loss and cost systems
2. Auditing
3. Internal auditing
4. External auditing
5. Uses and management of funds
Accounting MIS
1. Provides aggregated information on accounts payable, accounts receivable,
payroll, and other applications.
2. Smaller companies may retain an outside accounting firm to assist in
accounting functions.
MIS for Competitive Advantage
1. Provides support to managers as they work to achieve corporate goals.
2. Enables managers to compare results to established company goals and identify
problem areas and opportunities for improvement.

45
 According to John Doolittle,
Developments in medical technology have long been confined to procedural or
pharmaceutical advances, while neglecting a most basic and essential component
of medicine: patient information management.
 According to Paul Farmer,
It is clear that the pharmaceutical industry is not, by any stretch of the
imagination,doing enough to ensure that the poor have access to adequate medical
care.

46
SALES , OVERHEADS AND NET PROFIT OF COMPANIES OF UNIKIND
PHARMA as on March 2015
SALES
COMPANIES SALES IN 2015 SALES IN 2014 PERCENTAGE CHANGE IN SALES
PFL-1
148101816 134084809
110%
PFL-2
38835434 82873850
47%
PFL-3
25122586 19815029
127%
MEDIFORCE
51591647 65831709
78%
SRL
129717207 113824021
114%
COPMED-1
39754873 30011618
132%
COPMED-2
272386109 276835750
98%
COPMED-3
14647997 28869579
51%
RELAX-1
46458942 110097670
42%
RELAX-2
224294325 234223465
96%

47
OVERHEADS
COMPANIES
OVERHEADS IN
2015
OVERHEADS IN
2014
PERCENTAGE CHANGE IN
OVERHEADS
PFL-1
9353212 9264452
101%
PFL-2
5037284 3735640
135%
PFL-3
1594055 937075
170%
MEDIFORCE
6400464 6170462
104%
SRL
11022916 9216938
120%
COPMED-1
2123318 2223115
96%
COPMED-2
11182876 12601973
89%
COPMED-3
4140592 4591063
90%
RELAX-1
6266830 6789840
92%
RELAX-2
8816471 8435952
105%

48
NET PROFIT
COMPANIES NET PROFIT IN 2015
NET PROFIT IN
2014
PERCENTAGE CHANGE IN NET
PROFIT
PFL-1
15733948 13135083
120%
PFL-2
5244075 15039204
35%
PFL-3
2612145 3053341
86%
MEDIFORCE
8568007 14524424
59%
SRL
17722273 17698370
100%
COPMED-1
6828160 4230942
161%
COPMED-2
36010901 40962131
88%
COPMED-3
1491662 7150903
21%
RELAX-1
3285860 14917201
22%
RELAX-2
22060374 23857054
92%

49
RESEARCH METHODOLOGY
Introduction:
This study focused on the M.I.S. Report of the 10 companies of Pharma. I thoroughly
studied the M.I.S. Report and compared the sales, profits, overheads of all the companies
and found a lot of new things from it.
3.1 The objectives of the study are as following:
 Analyzing the M.I.S. Report of various pharmaceutical companies.
 Finding the areas where the companies can invest in next year .
 Finding the areas where the companies can reduce their expenses.
 Measuring the increased or decreased sales of various companies by comparing
their sales from last year.
3.2 DIFFERENT RESEARCH DESIGN:-
Research design can be commonly described if we categorize them as:-
 Exploratory research design.
 Descriptive research design
EXPLORATORY RESEARCH STUDY:
The major purpose of exploratory research is to identify the problem more specifically.
Exploratory research studies are used in the initial stages of the research. The focus is the
exploratory researches discovery of ideas.

50
DESCRIPTIVE RESEARCH STUDY:
A research to describe something. Descriptive studies can tell us proportions of high and
low income customer in a particular territory. Objective of the study is to answer the
who, what, when, where and how the subject.
I used descriptive research in my report because I have taken the sales, overheads and net
profit from 10 pharmaceutical companies of Paonta Sahib.
3.3 DATA COLLECTION
 Primary data
 Secondary data
Primary Data: that is through the discussion with the various officers working in the
various sections of the finance department.
Secondary Data: data collected by other persons and which have already been passed
through the statistical process.
Sources of secondary data: reports and accounts for the concerned company for the last
4-5 years. Company records & profile.
I used the primary data in my report as I am having M.I.S. report of 10 pharmaceutical
companies on which I had done the research.

51
Data Analysis and Interpretation
PHARMA FORCE LABS UNIT-I
Description 2015 2014
Sales Value 148,101,816 134,084,809
Material Consumed 123,014,657 111,685,275
Net Contribution (NC) 25,087,159 22,399,535
Power & DG Expense 1,052,517 1,187,347
Consumable Expenses 380,579 254,199
Laboratory & Testing Expense 557,171 430,155
Salary & Wages Expenses 3,427,295 3,747,559
Repair & Maintenance Expenses 411,757 792,644
Others 3,523,892 2,852,548
Total Overheads (OH) 9,353,212 9,264,452
Profit before Tax (PBT) 15,733,948 13,135,083
 INTERPRETATION:-
The sales of PFL-I has increased by 9.46% but the overheads are almost same. The
overheads are not increasing which is a good sign for the future of the company. The unit
is growing very fast as the profit of the company has increased by 16.51% as compared to
last year.The repair and maintenance expenses of P.F.L.-1 have reduced by 50% as
compared to last year which is a very good sign for the future of the company.

52
PHARMA FORCE LABS UNIT-II
Sales Value 38,835,434 82,873,850
Power & DG Expense 1,262,975 648,449
Laboratory & Testing
Expense 92,927 146,718
Repair & Maintenance
Expenses 152,788 107,726
Others 1,099,954 1,479,915
The sales of PFL-II & COPMED-I is almost same in current year that is Rs. 38835434
and Rs. 39754873 respectively but there is huge difference in the overheads of both the
companies, the overheads of P.F.L.-II are increased by 31% and due to this the PFL-II is
having less profit as compared to last year profit which is reduced by 76%. The sales of
this unit is reduced by 53% as compared to last year. The power & DG expenses are
increased by 94% as compared to last year. The salary and wages expenses are almost
doubled but the sales are reduced by 53% as compared to last year.

53
PHARMA FORCE LABS UNIT –III
Sales Value 25,122,586 19,815,029
Power & DG Expense 242,095 346,478
Salary & Wages Expenses 451,598 402,416
Others 659,371 132,943
Total Overheads (OH) 1,594,055 937,075
The sales of P.F.L.-III has increased by 27% as compared to previous year but the
overheads of P.F.L.-III have increased by 70% which resulted in reduction of net profit
by 14% as compared to last year. The consumable expenses and others have increased by
a huge percentage which has fallen the net profit by 14%.

54
MEDIFORCE HEALTHCARE PVT.LTD.
Sales Value 51,591,647 65,831,709
Power & DG Expense 976,640 1,050,362
Laboratory & Testing Expenses 177,718 184,631
Others 1,901,626 1,980,502
The sales of Mediforce has declined by 22% and overheads increased by 4% as compared
to last year. When the sales are declining then overheads must also decline but in
mediforce the overheads are increasing that’s why the net profit has fallen by 4% which
is not good for future of company. The main cause of increase in overheads is that the
repairs & maintenance expenses have increased by 94% as compared to last year.

55
SIRMOUR REMEDIES PVT.LTD.
Sales Value 129,717,207 113,824,021
Power & DG Expense 1,231,285 988,693
Expense 529,649 641,909
Expenses 601,948 490,472
Others 4,740,592 2,530,172
The sales of SRL has increased by 14% as compared to last year overheads by 20% but
the profit of company is same as that of last year. The power expenses, repair expenses
and other overheads have increased as compared to last year.

56
COPMED PHARMACEUTICALS PVT. LTD. UNIT –I
Sales Value 39,754,873 30,011,618
Power & DG Expense 293,152 361,819
Salary & Wages Expenses 922,836 913,489
Expenses 190,573 119,120
Others 568,778 588,060
The sales of Copmed-I has increased by 32% as compared to last year and the
overheads has decreased by 4% which is a good sign for the company and I is
growing very fastly. The net profit of the company has increased by 61% as
compared to last years net profit. The power and other expenses have reduced as
compared to last year due to which the sales and profits of the company have
increased.

57
COPMED PHARMACEUTICALS PVT. LTD. UNIT –II
Sales Value 272,386,109 276,835,750
Power & DG Expense 2,991,847 1,772,737
Expenses 808,698 1,430,881
Others 3,466,715 5,036,689
The sales of Copmed II has decreased by 2% in May 2015 as compared to May 2014 and
the overheads of the company are reduced by 12% but the net profit has reduced by 12%.
This indicates that with decrease in the overheads also the net profit of the company has
not increased as compared to last year.

58
COPMED PHARMACEUTICALS PVT. LTD. UNIT-III
Sales Value 14,647,997 28,869,579
Power & DG Expense 962,785 1,311,756
Others 999,572 1,074,717
Sales of COPMED-III had fallen by 49% as compared to sales of last year but the
overheads has reduced only by 10% which is not reduced in that proportion in which
sales are reduced which is not a good sign for the future of the company. The net
profit had fallen by 79% as compared to last year.

59
RELAX PHARMACEUTICALS PVT. LTD. UNIT –I
Sales Value 46,458,942 110,097,670
Power & DG Expense 1,195,341 1,439,052
Laboratory & Testing Expenses 70,475 170,395
Others 1,713,721 1,419,320
The sales of Relax I has decreased by 58% as compared to last year but the overheads has
only decreased by 8% which is very high as compared to fall in sales and the net profits
has reduced to the lowest of all units that is 78%. The reduction in sales had lead to less
net profits as compared to last year.

60
RELAX PHARMACEUITICALS PVT. LTD. UNIT-II.
Sales Value 224,294,325 234,223,465
Power & DG Expense 1,405,762 1,280,471
Expenses 415,149 352,498
Salary & Wages
Expenses 3,509,566 3,420,091
Expenses 478,403 712,346
Others 2,751,833 2,414,806
The sales of Relax II has declined by 4% and the overheads declined by 4% as compared
to last year but the net profit has declined by 8%. The status of company has not fallen so
much but Net Profit has declined more as compared to last year.

61
FINDINGS
1. After the research on M.I.S. report of 10 companies of Pharmaceutical Industry, I
came to know that the sales of companies such as P.F.L.-I, P.F.L.-III, S.R.L.,
Copmed-I have increased as compared to their sales in the last year. But the sales
of the companies such as P.F.L.-II, Mediforce, Copmed-II, Copmed-III, Relax-I,
Relax-II have continuously decreased as compared to last year sales.
2. The overheads of such as P.F.L.-I, Copmed-I, Copmed-II, Copmed-III, Relax-I,
Relax-II have decreased as compared to last year’s expenses which is a good sign
for the company. But the overheads of companies such as P.F.L.-II, P.F.L.-III,
Mediforce, S.R.L. have increased as compared to last year’s overheads.
3. The net profits of the companies such as P.F.L.-I, Copmed-I have increased as
compared to last years net profit of these companies. But the net profit P.F.L.-II,
P.F.L.-III, Mediforce, S.R.L., Copmed-II Copmed-III, Relax-I, Relax-II have
reduced as compared to the net profits of the last year.

62
RECOMMENDATIONS
1. The companies whose sales have increased as compared to previous year’s sales
should maintain their selling level so that in coming future their sales will
increase more as compared to current year’s sales. But the companies whose sales
have declined as compared to last year’s sales they must use some new strategies
so that their can be increased in coming future and their sales must increase every
year so that companies can earn more profits.
2. The overheads of some companies have increased at a very high speed as
compared to their overheads in the last year, they must control expenses so that
they can effectively and efficiently so that they can more and more profits.
3. In some companies on which I did the research, net profit have increased as
compared to net profit of last year, these companies must maintain their sales
efficiency and control the overheads in the same way they are doing now so that
in coming year they can earn more profits. But some companies’ net profit had
decreased as compared to last year’s net profit of those companies, they should
control their overheads and change their selling techniques so that they can
increase their sales and then net profit can be increased.

63
CONCLUSION
So in the end to conclude we can say all the 10 companies are earning profits no unit is
under any loss. In the analysis of M.I.S. report of the all 10 companies there are some
units which are earning the more percentage of net profit as compared to that of the net
profit of the last year of that unit and where as in some of the units the percentage in net
profit has fallen as compared to last year’s net profit. The sales of units like Copmed-II
Pharmaceuticals, Copmed-III Pharmaceuticals, Relax-I Pharmaceuticals, Relax-II
Pharmaceuticals and Mediforce Pharmaceuticals have decreased as compared to the sales
of last year. These units must check upon their sales strategies and if there is any need of
change in the strategies then it must be changed. The above units must check the
overheads and find out ways how to reduce the overheads so that the sales and the net
profits of the units must increase.
The units like Pharma Force Labs-I, Pharma Force Labs-II, Pharma Force Labs-III, and
Copmed-I Pharmaceuticals and Sirmour Remedies Pvt. Ltd. have increased their sales
and net profit as compared to last year’s sales and net profit. They must maintain their
sales strategy and must check the overheads and if it can be decreased then it must be.
The net profits can only be increased if the sales are increased and overheads are
decreased. Employees should be trained according to the changing standards of the
organization. Company should conduct survey from time to time according to which
changes can be introduced in the organization to stay updated in the market. They should
introduce creativity into the work, so that the employees can do their work passionately.
Employees should be more involved in decision making to become more differentiated.

64
BIBLIOGRAPHY
All the information gathered to compete the project has been collected from the following
sources
1. M.I.S. Reports of 10 pharmaceutical companies
2. Company Website
3. Other Websites
www.google.com
www.wikipedia.com
4. Journals
The Management Accountant, January 2014
The Management Accountant, February 2014
The Management Accountant, June2014
5. Some links from internet
http://www.inc.com/encyclopedia/management-information-systems-mis.html
http://www.webopedia.com/TERM/M/MIS.html

Nikroxx file pdf

More Related Content

What's hot

Similar to Nikroxx file pdf

Recently uploaded

Nikroxx file pdf